The gastro-retentive drug delivery systems market is anticipated to produce sales of US$ 13.3 billion in 2022 and is projected to grow at a CAGR of 10.1% from 2023 to 2033, according to a recently released Future Market Insights analysis. By the end of 2033, the market is projected to reach US$ 24.8 billion.
Large drug firms’ investments to enhance gastro-retentive drug-delivery systems, along with the reduction in required doses due to enhanced bioavailability and an increase in the requirements for medications, have helped accelerate the market growth. The well-established efficacy of gastro-retentive drug delivery systems in treating a variety of stomach disorders such as peptic ulcer and gastric ulcer, as well as a growth in the incidence of H. Pylori infection, which can cause gastritis and gastric cancer, impart a significant impact on the market.
Unleash the extraordinary. Claim your sample for unmatched efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16540
Gastro-retentive drug distribution technology has proven to be a useful way of regulating the administration of a wide range of medicinal substances while enhancing bioavailability. Advancements in controlled oral medication administration systems have been made in recent years because of technological advancements that overcome physical roadblocks such as unpredictable stomach emptying periods and short gastric residency times. By extending their dwell time in the upper GI tract, once-GRDDS can enhance oral bioavailability and therapeutic excellence.
Technological advancements for rate-controlled oral medication delivery systems are now overcoming physiological issues such as unexpected stomach emptying intervals and short gastric residency times. To address these issues, the gastro-retentive drug delivery system is designed for a longer stomach retention duration, which increases patient preference by extending the time available for medicine absorption.
North America is expected to account for significant revenue in the gastro-retentive drug delivery systems market, with a market projection of US$ 10 Billion. Regional expansion is expected to be facilitated by the introduction of improved gastro-retentive medication delivery technology and the implementation of novel treatment techniques in healthcare.
GRDDS are projected to be in high demand as the prevalence of gastrointestinal disorders grows in the United States and Canada, as they lengthen medication retention time in the stomach. Demand for these devices in the region is projected to be driven by the presence of a large patient pool. Rising research and development spending in emerging markets is expected to drive regional market expansion.
Competitive Analysis
Manufacturers will benefit from proprietary benefits such as industry research financing and product development agreements, which will help them contribute to the development of effective cancer diagnosis technologies. Obtaining patents and government clearances for new technology will also continue to be a key growth strategy. The key players in the market include Ranbaxy, F. Hoffmann La Roche, Pharmacia, GlaxoSmithKline, Lupin, Pfizer, Depomed, Galanix, Sun Pharma, and Alcon, Inc.
Few of the recent developments of key Gastro-retentive Drug Delivery Systems providers are as follows:
- In 2020, Cadila Pharmaceuticals launched Esomeprazole tablets which will be used in treatment of hyperacidity and drug induced gastritis.
- In 2020, Xiromed LLC launched 20mg Omperazole delayed release capsules. Omeprazole is cost effective generic product which can be used in treatment of gastroesophageal reflux disease and healing of erosive esophagitis.
Market Segments Covered in Gastro-retentive Drug Delivery Systems Industry Analysis
By Type:
- High Density System
- Expandable Drug Delivery System
- Bioadhesive Drug Delivery System
- Floating Drug Delivery System
- Others
By Dosage Form:
- Tablets
- Liquid
- Microspheres
- Capsule
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
